David P. Della Camera Becomes CFO of First Interstate BancSystem, Inc.
BILLINGS, Mont.--(BUSINESS WIRE)--First Interstate BancSystem, Inc. (NASDAQ: FIBK) (“First Interstate” or the “Company”) announced that effective June 1, 2025, David...
Morning Movers
Super League Enterprise, Inc. Announces Closing of Registered Direct Offering
SANTA MONICA, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Super League Enterprise, Inc. (NASDAQ: SLE) (the “Company”), a leader in...
Super League Enterprise, Inc. Announces the Closing of Underwritten Public Offering
SANTA MONICA, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Super League Enterprise, Inc. (NASDAQ: SLE) (the “Company”), a leader in...
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase...
Resouro Strategic Metals Inc. to Attend THE Mining Investment Event in Quebec City
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2025) - Resouro Strategic Metals Inc. (ASX: RAU) (TSXV: RSM) (FSE: 8TX) (OTCQB: RSGOF)...
SOL Strategies Reports Q2 Results and May Strategic Update
Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - SOL Strategies Inc. (CSE: HODL) (OTCQB: CYFRF) (formerly, Cypherpunk Holdings Inc, "Sol...
Plurilock Security Inc. Reports Record First Quarter Fiscal 2025 Financial Results
178% year-over-year increase in Critical Services revenue28% year-over-year increase in Gross Profit to $2.3 millionVancouver, British Columbia--(Newsfile Corp. - June...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion...
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European...
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median...
Success for Lottery.com and Sports.com in Detroit as Seb Murray Secures Career-Best INDY NXT Finish
DETROIT, June 02, 2025 (GLOBE NEWSWIRE) -- It was a weekend of milestones and resilience for Lottery.com Inc. (Nasdaq: LTRY,...
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four...
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing...
Guardian Pharmacy Services Expands Pacific Northwest Footprint with Acquisition of Washington-based Mercury Pharmacy Services
ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s largest and most innovative long-term care (LTC) pharmacy services...
Kenneth Lamneck Joins TD SYNNEX Board of Directors
FREMONT, Calif. & CLEARWATER, Fla.--(BUSINESS WIRE)--TD SYNNEX (NYSE: SNX) welcomed Kenneth Lamneck to its Board of Directors (the “Board”) at...
Canadian Gold Corp. Acquires Assigned Option from Searchlight Resources Inc. of Flin Flon North Property, Significantly Expanding Control of the Tartan Shear Zone
Flin Flon, Manitoba--(Newsfile Corp. - June 2, 2025) - Canadian Gold Corp. (TSXV: CGC) ("Canadian Gold" or the "Company") is pleased...
Diana Shipping Inc. Announces Time Charter Contract for m/v Newport News With Bohai Ocean Shipping
ATHENS, Greece, June 02, 2025 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing...
OceanPal Inc. Announces the Sale of M/V Protefs
ATHENS, Greece, June 02, 2025 (GLOBE NEWSWIRE) -- OceanPal Inc. (NASDAQ: OP) (the “Company”), a global shipping company specializing in...
Cemtrex’s Vicon Expands Leadership in UK Prison Security Market with New Wave of System Orders
Hauppauge, NY, June 02, 2025 (GLOBE NEWSWIRE) -- Vicon Industries, a subsidiary of Cemtrex Inc. (Nasdaq: CETX) and a...
BTQ Technologies Unveils Breakthrough Performance of CASH Architecture, Paving the Way for the Future of Quantum-Secure Devices
BTQ's CASH architecture delivers industry-leading cryptographic performance, processing up to 1 million digital signatures per second and executing encryption tasks...
Cloudflare and TD SYNNEX Expand Partnership to Secure Latin America with Managed Services
MEXICO CITY & SÃO PAULO--(BUSINESS WIRE)--Cloudflare, Inc. (NYSE: NET), the leading connectivity cloud company, and TD SYNNEX (NYSE: SNX), a...
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four...
Lightbridge Completes Final Experiment Design for Designated ATR Core Position
RESTON, Va., June 02, 2025 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), a leader in advanced nuclear fuel technology, today...
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
- Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal...
IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival
Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months...
Cloudflare and TD SYNNEX Expand Partnership to Secure Latin America with Managed Services
MEXICO CITY & SÃO PAULO--(BUSINESS WIRE)--Cloudflare, Inc. (NYSE: NET), the leading connectivity cloud company, and TD SYNNEX (NYSE: SNX), a...
Fifth Third Bank, National Association, Names Scott Daigle as North Florida President, Cary Putrino as Region Chairman
TAMPA, Fla.--(BUSINESS WIRE)--Fifth Third Bank, National Association, (Nasdaq: FITB) has announced Scott Daigle as North Florida region president. Daigle succeeds...
CEO.CA’s Inside the Boardroom: Sterling Metals Hits 4 Football Fields of Copper Near Surface
Toronto, Ontario--(Newsfile Corp. - June 2, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture...
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June...
BTCS Inc. Utilizes Crypto.com and Acquires 1,000 ETH, Expanding Ethereum Holdings to 13,500 ETH
Silver Spring, Maryland--(Newsfile Corp. - June 2, 2025) - BTCS Inc. (NASDAQ: BTCS) ("BTCS" or the "Company"), a blockchain technology-focused...
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion...
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical...
Endo Champions Men’s Health Month with Education, Awareness, and Outreach
MALVERN, Pa., June 2, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today its Men's Health Month initiative, reaffirming its...
Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor...
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7...
Aqua Metals Announces Allowance of Foundational U.S. Patent for Lithium Battery Recycling Technology
RENO, Nev., June 02, 2025 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a leader in sustainable lithium battery recycling, today...
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania
NEW YORK--(BUSINESS WIRE)--Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today...
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’...
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to...
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing...